Comment on “Homeobox B2 is a potential prognostic glioblastoma biomarker”

Renwen Xing¹, Lianping He², Yuanlong Gu³, Yonghua Mou¹*

Dear Editor,

We read the study by Ming Li¹ and colleagues with great interest, in which they revealed the impact of HOXB2 on the prognosis of glioma and its possible role through the PI3K/AKT signaling pathway. This work has a certain degree of guiding significance for the further exploration of disease mechanisms and clinical prognosis evaluation. But there are still a few questions. I want to discuss this with the author and colleagues.

Firstly, Although the current research displays that all types of tumors may have the same basic driving and evolution mechanism, different types of tumors are still considered to have different pathological characteristics during the occurrence and development process, which has also led to the clinical evolution of different tumors. The prognosis is different. The author points out that the Homeobox B2 gene has a prognostic function in lung cancer research, and further deduces that the Homeobox B2 gene has a similar function in glioma. There is no direct connection between them, and the scientific hypothesis is not rigorous enough.

Secondarily, the role of the homeobox B2 gene in the PI3K/Akt signaling pathway is not explained clearly in this paper. All the molecular biology experiments in vitro are to demonstrate the role of the homeobox B2 gene in the PI3K/Akt signaling pathway. We suggest that the author should show the PI3K/Akt signaling pathway graphically and explain the role of the PI3K/Akt signaling pathway in the evolution of glioma. In this way, readers can better understand the significance of the author’s scientific research, and enlighten relevant scholars for further research work.

AUTHORS’ CONTRIBUTION
RX: Data curation, Formal Analysis, Writing – original draft.
LH: Investigation, Visualization.
YG: Resources, Investigation.
YM: Conceptualization, Funding acquisition, Project administration, Writing – review & editing.

REFERENCE

¹Taizhou Municipal Hospital Emergency Medical Service, Department of Hepatobiliary Surgery – Zhejiang, China.
²Taizhou Municipal Hospital Emergency Medical Service, School of Medicine – Zhejiang, China.
³Taizhou Municipal Hospital Emergency Medical Service, Department of Hematology Oncology – Zhejiang, China.
*Corresponding author: xiaowaishiyan@163.com
Conflicts of interest: the authors declare there are no conflicts of interest. Funding: This study was supported by Zhejiang Medicine, Health and Science grant 2018KY902.
Received on February 10, 2021. Accepted on March 14, 2021.